Other drugmakers have abandoned their search for a drug to prevent premature ejaculation, but Johnson & Johnson, whose first try was rejected by the FDA, is still in the hunt. The company intends to test its dapoxetine outside the U.S. and file for regulatory approval in Europe and Canada later this year. The FDA declined to approve it in 2005, questioning its medical benefit.

Related Summaries